COMMUNIQUÉS West-GlobeNewswire

VitalHub Announces Q3 2025 Conference Call Date
20/10/2025
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the "Company" or "VitalHub") announced today that it will release financial results for its third quarter 2025 ended September 30, 2025 [...]
ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025
20/10/2025
SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial [...]
Eleos to Launch Polaris AI Advanced, Purpose-Built Foundational AI Model for Post-Acute Care, built with Google Cloud Technology
20/10/2025
Polaris AI leverages Google Cloud’s Gemini family of multimodal models and Eleos’ secure and clinically validated infrastructure to reduce documentation burden, strengthen compliance and help providers focus on care. [...]
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
20/10/2025
OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit , taking place October 22-23, 2025 in [...]
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conference call on 4 Nov 2025 at 11.00 CET
20/10/2025
Tuesday, 4 November 2025 at 11:00 - 12:00am CET In connection with the publication of Coloplast’s interim financial results for FY 2024/25, to be released same day around 07.00am CET, Coloplast will host a conference [...]
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
20/10/2025
– Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including pain, compared to [...]
Angelini Ventures Deepens Commitment to CoMind, a Neurotech Redefining Brain Monitoring, with Participation in $60 Million Round Bringing Total Funding to $102.5 Million
20/10/2025
CoMind's optical brain sensing technology uses laser light delivered through a removable sensor to provide continuous, non-invasive brain monitoring without need for surgery Advancing brain health is a strategic [...]
Aicuris Presents Positive Phase 2 Results for Pritelivir and Favorable Phase 1 Safety Data for AIC468 at ID Week 2025
20/10/2025
Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnet Pritelivir Phase 2 results supported FDA Breakthrough Therapy Designation and [...]
The Ensign Group Schedules Third Quarter Earnings Call for Tuesday, November 4, 2025
20/10/2025
SAN JUAN CAPISTRANO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025
20/10/2025
LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30 [...]
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
20/10/2025
LEXINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
RadNet, Inc. Announces Date of its Third Quarter 2025 Financial Results Conference Call
20/10/2025
LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
20/10/2025
Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner’s National Priority Voucher ( [...]
WeightWatchers Collaborates With Amazon Pharmacy to Increase Medication Delivery Speed, Convenience and Savings For Members
20/10/2025
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced a collaboration with Amazon [...]
BioCryst to Report Third Quarter 2025 Financial Results on November 3
20/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, [...]
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
20/10/2025
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments [...]
J-Star Applauds the Cooperation of Nasdaq and Ho Chi Minh City to Develop an International Financial Center in Vietnam
20/10/2025
TAICHUNG CITY, Taiwan, Oct. 20, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of [...]
BPGbio and Icahn School of Medicine at Mount Sinai Publish Landmark Study on the Living Human Brain, Unlocking New Molecular Insights Into Neurodegenerative Disease
20/10/2025
New findings challenge the longstanding assumption that postmortem tissue accurately represents the living brain — and can reshape the future of research and drug development for Alzheimer’s, Parkinson’s, and other [...]
Medicenna Therapeutics Announces Participation in Upcoming Conferences
20/10/2025
TORONTO and HOUSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]

Pages